Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone am...
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
About this item
Full title
Author / Creator
Publisher
Cham: Springer Science + Business Media
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer Science + Business Media
Subjects
More information
Scope and Contents
Contents
Purpose
To compare the quality-adjusted survival of nivolumab plus ipilimumab combination and nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma based on a minimum 36-month follow-up from the CheckMate 067 trial.
Methods
Overall survival was partitioned into time without symptoms of progression or...
Alternative Titles
Full title
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2100105860
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2100105860
Other Identifiers
ISSN
0962-9343
E-ISSN
1573-2649
DOI
10.1007/s11136-018-1984-3
